Kyowa Kirin Q2 2025 slides: profit falls 57% amid restructuring, pipeline advances

Kyowa Kirin (TYO:4151) reported a significant 57% year-over-year profit decline in Q2 FY2025 to ¥16.3 billion, primarily driven by ¥10.5 billion in restructuring costs, despite key strategic products like Crysvita (+10%) and Poteligeo (+14%) showing robust sales growth. While H1 revenue slightly decreased and core operating profit fell 21%, the Japanese pharmaceutical firm maintained its full-year guidance, signaling confidence in its pipeline advancements. Notably, its AML treatment ziftomenib received FDA Priority Review with a PDUFA date of November 30, 2025, following positive Phase 2 data, and its atopic dermatitis drug rocatinlimab is progressing in Phase 3, positioning the company for potential future growth amidst ongoing challenges from Japanese drug price reductions and global competition.

Analysis

Kyowa Kirin (TYO:4151) reported a significant 57% year-over-year profit decline to ¥16.3 billion in Q2 FY2025, primarily driven by ¥10.5 billion in business restructuring expenses, including a ¥9.4 billion early retirement program. This led to a 21% decrease in core operating profit and a 1% revenue dip for the first half. However, strategic products like Crysvita (+10% to ¥99.8 billion) and Poteligeo (+14% to ¥21.6 billion) showed strong sales growth.

R&D expenses increased to 23% of revenue, reflecting continued pipeline investment, notably impacted by Orchard Therapeutics consolidation. Geographically, North America demonstrated robust growth of ¥9.6 billion, contributing to an increased overseas revenue ratio of 73%. Conversely, Japan's revenue declined by ¥6.9 billion due to sales partnership terminations and national health insurance price cuts.

The company's pipeline shows significant promise, with ziftomenib, an AML treatment, receiving FDA Priority Review and a PDUFA date of November 30, 2025, following positive Phase 2 data (33% ORR). Rocatinlimab for atopic dermatitis is also progressing well in its Phase 3 ROCKET program. Despite H1 challenges, Kyowa Kirin maintained its full-year guidance, signaling confidence in its strategic initiatives, including leveraging AI for promotional activities, and its long-term Vision 2030.

Key Decisions for Investors

• Investors should monitor the FDA PDUFA date for ziftomenib on November 30, 2025, as a significant near-term catalyst for the company's valuation.
• Evaluate the effectiveness of the recent restructuring efforts and their impact on future profitability, distinguishing one-off costs from underlying operational trends.
• Assess the continued growth trajectory of key strategic products like Crysvita and Poteligeo, alongside the company's ability to offset challenges in the Japanese market through international expansion.